>PARTNERSHIP >Partnering with Takeda
At Takeda, partnerships are at the heart of what we do. Almost one third* of our revenues come from partnerships and strategic acquisitions, and that will grow to over 50 percent by 2015*. We have significant experience in developing mutually beneficial discovery, development and commercial relationships. Our dedicated alliance management function fosters strong relationships throughout the product life cycle, from early development to late stage. Our teams apply Takeda's core values of perseverance, honesty and fairness to each collaboration.
Takeda has always valued innovation. We have a history of acquiring companies with strong scientific platforms and expertise – Syrrx(now Takeda California), Paradigm Pharmaceuticals (now Takeda Cambridge and Takeda Singapore) and Millennium Pharmaceuticals (now Millennium: The Takeda Oncology Company). We invest in them, allowing them to flourish and achieve their full potential.
Takeda has a proven track record in Research and Development, having brought leading treatments to market for diabetes, gastrointestinal disorders and cancer. We spend more than 20 percent of our revenues on R&D, one of the highest investments in the industry.
We also have a global and highly respected expertise in product commercialization in our core therapeutic areas. Our acquisition and integration of Nycomed has not only strengthened our pan-European platform, but also expanded our sales channels into emerging markets, offering integrated global product development.
Our highly efficient and adaptable worldwide manufacturing network has the ability to produce diverse products applying a wide range of technologies, from API to production and packaging of solid, semi-solid, liquid and injectable pharmaceuticals. With the know-how and the capacity of our manufacturing plants throughout the world, we are close to our customers in far-reaching markets.
Collectively these capabilities mean that, with our partners, we are uniquely positioned to develop new products and to commercialize existing products in markets around the world. We can strive together to achieve the best outcomes for our patients.
*including Nycomed acquired in 2011
As of end of March 2013
We are proud of our global footprint and offer our partners access to our worldwide expertise in product development and commercialization, which is supported by our state-of-the-art R&D facilities around the world, and our global manufacturing and supply chain networks.
We have strong sales and marketing capabilities and local regulatory expertise in more than 70 countries across the world. With a substantial presence in Japan, Asia, North America and Europe and a leading position in the key high growth emerging markets, we have the resources to make our products and our partners' products a global success.
Our robust research and development network spans the world to facilitate the global launch of products. Takeda has a proven track record in research and development, having brought leading treatments to market. Our pipeline is the 7th largest amongst the global pharma industry and we expect to launch more than 17 products in the coming years, over half of which are from partnerships. Together, we can improve the health of people around the world.
Our global supply chain network includes plants on three continents, ensuring that we are always close to customers. We deliver a diverse portfolio meeting global and local needs, and can adapt to volatile demand in emerging markets.